Table 2.
The pharmacokinetics of AWD21-360 after administration of retigabine alone or with phenobarbitone.
| Subject group | Cmax (ng ml−1) | tmax (h) | t½ (h) | AUC (ng ml−1 h) | AUCm : AUC |
|---|---|---|---|---|---|
| Alone (n = 15)a | |||||
| Mean ± SD | 318 ± 71 | 3.5 ± 1.0 | 6.8 ± 1.5 | 3638 ± 802 | 0.99 ± 0.19 |
| Geometric mean | 311 | 3.3 | 6.6 | 3562 | 0.98 |
| With phenobarbitone (n = 13)a | |||||
| Mean ± SD | 586 ± 99 | 2.6 ± 1.8 | 7.7 ± 1.9 | 3622 ± 628 | 0.93 ± 0.33 |
| Geometric mean | 579 | 2.5 | 7.5 | 3572 | 0.89 |
| P values for transformed analysis of variance with factor for | |||||
| Treatment | NAb | 0.14 | 0.05 | 0.90 | 0.52 |
| Geometric mean ratio | NA | – | 110 | 101 | – |
| 90% confidence limits | NA | – | 102, 118 | 88, 116 | – |
a
Alone: retigabine 200 mg single dose; With phenobarbitone: retigabine 200 mg every 8 h.
b
NA not available. It is not appropriate to compare Cmax between single dose and multiple doses.